ERBB2 and breast cancer: In contrast, the costs of treatment for HER2-positive patients would be expected to increase as patients diagnosed at earlier stage of BC (stage I–III) tend to opt for targeted therapy, while patients diagnosed with metastatic BC (stage IV) chose chemotherapy only to save cost.